

www.tajpharma.com

TRELNOR® (dalfampridine), an oral medication, is the only treatment shown to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. Not everyone responds to TRELNOR. Individual results may vary. In a poll of more than 2000 people with MS, walking was named as one of the most challenging aspects of MS — 87% of people with MS said they had some limitations in their walking ability and limited activities that involved walking.\*

**trelnor**  
(dalfampridine) 10 mg  
Extended Release Tablets

Treatment for: Multiple Sclerosis  
Trelnor (dalfampridine) is an oral potassium channel blocker indicated to improve walking ability in people with multiple sclerosis.  
\*Trelnor can be taken with or without food.



**trelnor**  
(dalfampridine) 10 mg  
Extended Release Tablets

Trelnor® (dalfampridine) Extended Release Tablets, 10 mg has been approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

TRELNOR is the first and only MS therapy that has been specifically approved by the FDA to improve walking in people with MS. More than 4500,000 people worldwide and nearly 2.5 million people worldwide are living with MS<sup>1</sup>, and for the majority of those people, the disease affects their ability to walk<sup>2</sup>. Improved walking can have a meaningful impact on the lives of people with MS and their caregivers, and we are gratified to have been able to contribute to advancing the care of people with MS.

Walking better matters. TRELNOR® (dalfampridine), an oral medication, is the only treatment shown in two clinical trials to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. TRELNOR improved walking in significantly more people with MS than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%).

Not everyone responds to TRELNOR. Individual results may vary.

TRELNOR® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

#### IMPORTANT SAFETY INFORMATION

Take the next step by asking your doctor about TRELNOR® (dalfampridine) – an oral medication and the only treatment shown to improve walking in people with multiple sclerosis (MS).

#### How to Take TRELNOR

Take TRELNOR® (dalfampridine) exactly as your doctor tells you to take it. Do not change your dose of TRELNOR. Take one tablet of TRELNOR 2 times each day about 12 hours apart. Do not take more than 2 tablets of TRELNOR in a 24-hour period.

#### Managing Your Treatment

Whenever you start a medication, it's important to take it as prescribed

Work with your healthcare team to stay on track with your TRELNOR® (dalfampridine) treatment. TRELNOR, an oral medication, is the only treatment shown to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. TRELNOR improved walking in significantly more people than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%).

**Food and Drug Administration (FDA) approved .Prescription Only (POM)**

A Taj Pharma™ India Product